How safe is emergency contraception?

Drug Safety

Volumn 25, Issue 10, 2002, Pages 695-706

  Turner, Abigail Norris ^a   Ellertson, Charlotte ^a  

^a POPULATION COUNCIL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; COPPER INTRAUTERINE DEVICE; CYCLOSPORIN; CYPROTERONE; DESOGESTREL; DESTODENE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; GESTODENE; GRISEOFULVIN; LEVONORGESTREL; LEVORA; LOW OGESTREL; LYNESTRENOL; MECLOZINE; MIFEPRISTONE; NORETHISTERONE; NORGESTREL; OGESTREL; ORAL CONTRACEPTIVE AGENT; PHENAZONE; PHENYTOIN; POSTCOITUS CONTRACEPTIVE AGENT; PRIMIDONE; THEOPHYLLINE; TRIVORA; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTERY DISEASE; CHINA; CHRONOPHARMACOLOGY; CLINICAL TRIAL; CONTRACEPTION; DRUG ABUSE; DRUG COMPETITION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY CONTRACEPTION; FEMALE; FEMALE FERTILITY; FOOD AND DRUG ADMINISTRATION; HEALTH HAZARD; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL RESEARCH; NAUSEA AND VOMITING; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEXUAL BEHAVIOR; TERATOGENESIS; TREATMENT FAILURE; VEIN DISEASE; WORLD HEALTH ORGANIZATION;

EID: 0036360476     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225100-00002     Document Type: Review

References (86)

1. Prescription drug products: Certain combined oral contraceptives for use as postcoital emergency contraception
2. Safety of emergency contraception
3. Contraception: A review
4. Oral contraceptives: Risks
5. Post coital contraception: A pilot study
6. Emergency contraception
7. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception
8. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception
9. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception
10. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen
11. Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse
12. Intrauterine contraceptive devices
13. Use of the intrauterine device: Efficacy and safety
14. Emergency contraception with multiload Cu-375 SL IUD: A multicenter clinical trial
15. Efficacy of emergency contraception: Topical reviews
16. The intrauterine device: Still misunderstood after all these years
17. Barriers to the use of IUDs as emergency contraception
18. Managing clinical complexities of long-term contraception
19. The economic value of contraception: A comparison of 15 methods
20. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception
21. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception
22. Mifepristone as a late post-coital contraceptive
23. Comparison of three single doses of mifepristone as emergency contraception: A randomised trial
24. How safe is the Yuzpe method of emergency contraception?
25. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case-control analysis
26. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives
27. Clotting factors after emergency contraception
28. The risk of venous thromboembolism in users of postcoital contraceptive pills
29. The risks of oral contraceptive pills
30. Current perspectives on oral contraceptive use
31. Oral contraceptives and the risk of myocardial infarction
32. Low-dose oral contraceptive use and the risk of myocardial infarction
33. Oral-contraceptive use in relation to myocardial infarction
34. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism
35. Emerging evidence on oral contraceptives and arterial disease
36. Noncontraceptive effects of hormonal contraceptives: Bone mass, sexually transmitted disease and pelvic inflammatory disease, cardiovascular disease, menstrual function, and future fertility
37. Fertility after contraception or abortion
38. Fertility after complicated and non-complicated use of IUDs: A controlled prospective study
39. Return of fertility in various types of IUD users
40. Fifteen years' experience with the Multiload IUD
41. Return of fertility in nulliparous women after discontinuation of the intrauterine device: Comparison with women discontinuing other methods of contraception
42. Intrauterine devices and infertility: Sifting through the evidence
43. Spermicides, hormonal contraception and congenital malformations
44. Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception
45. Teratogenic hazards of oral contraceptives analyzed in a national malformation register
46. Outcome of pregnancy in women using different methods of contraception
47. Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis
48. Emergency contraception
49. Bundling a pregnancy test with the Yuzpe regimen of emergency contraception
50. Mifepristone 100 mg in abortion regimens
51. The effectiveness of the Yuzpe regimen of emergency contraception
52. Ethinyl oestradiol plus dl-norgestrel or levonorgestrel in the Yuzpe method for postcoital contraception: Results of an observational study
53. Meclizine for prevention of nausea associated with use of emergency contraceptive pills: A randomized trial
54. Sexually transmitted infections
55. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: A literature review
56. Interactions between herbal medicines and prescribed drugs: A systematic review
57. Indinavir concentrations and St John's wort
58. Does St. John's Wort decrease OC efficacy?
59. Knowledge and perceptions of emergency contraceptive pills among a college-age population: A qualitative approach
60. Emergency contraception in Mexico City: What do health care providers and potential users know and think about it?
61. Emergency contraception in Nairobi, Kenya: Knowledge, attitudes and practices among policymakers, family planning providers and clients, and university students
62. Emergency contraception: Pediatricians' knowledge, attitudes, and opinions
63. Concerns and cautions about prescribing and deregulating emergency contraception: A qualitative study of GPs using telephone interviews
64. Not a 'proper' solution? The gap between professional guidelines and users' views about the safety of using emergency contraception
65. Repeated use of hormonal emergency contraception by younger women in the UK
66. The effects of self-administering emergency contraception
67. Emergency contraception: Advance provision in a young, high-risk clinic population
68. Efficacy and side effects of immediate postcoital levonorgestrel used repeatedly for contraception
69. Emergency contraception: Randomized comparison of advance provision and information only
70. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device
71. Intrauterine device and upper-genital-tract infection
72. Contraception in general practice before teenage pregnancy: Intrauterine device may not be suitable method of contraception for teenagers
73. Unintended pregnancy: Consequences and solutions for a worldwide problem
74. Family planning for the underserved: An IPPF perspective
75. Unintended childbearing in developing countries: Levels, trends, and determinants